Comment on "MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC".

J Thorac Oncol

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Electronic address:

Published: December 2024

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2024.08.016DOI Listing

Publication Analysis

Top Keywords

comment "muc1-c
4
"muc1-c common
4
common driver
4
driver acquired
4
acquired osimertinib
4
osimertinib resistance
4
resistance nsclc"
4
comment
1
common
1
driver
1

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!